Larimar Therapeutics, Inc. — Director's Dealing 2021

Jan 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Larimar Therapeutics, Inc. (LRMR)
CIK: 0001374690
Period of Report: 2021-01-19

Reporting Person: Celano Michael (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-19	Stock Option (Right to Buy)	$19.61	A	42000	Acquired	2031-01-19	Common Stock (42000)	Direct

Footnotes

F1: The option vests 25% on January 19, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.